Miyazaki Y, et al. - Researchers presumed a role of B cell-activating factor of the tumor necrosis factor family (BAFF) in the expression of an increased proportion of transitional B cells in the circulation of patients treated with fingolimod for multiple sclerosis (MS). This presumption was tested and it was found that in addition to expanding transitional B cells, fingolimod induced BAFF in the circulation. However, no fingolimod-triggered activation of memory B cells or plasma cells was observed in MS patients, which is favorable for the treatment of this disease.